Tejas Savant
Stock Analyst at Morgan Stanley
(2.33)
# 2,620
Out of 5,245 analysts
249
Total ratings
41.67%
Success rate
-1.53%
Average return
Main Sectors:
Stocks Rated by Tejas Savant
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PSNL Personalis | Maintains: Equal-Weight | $10 → $9 | $8.47 | +6.26% | 16 | May 12, 2026 | |
| CTKB Cytek Biosciences | Maintains: Equal-Weight | $6 → $5.5 | $4.01 | +37.16% | 10 | May 12, 2026 | |
| ADPT Adaptive Biotechnologies | Maintains: Equal-Weight | $21 → $18 | $13.88 | +29.68% | 14 | May 12, 2026 | |
| TXG 10x Genomics | Maintains: Equal-Weight | $20 → $22 | $23.68 | -7.09% | 17 | May 12, 2026 | |
| VCYT Veracyte | Maintains: Underweight | $48 → $37 | $45.03 | -17.83% | 16 | Mar 6, 2026 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $24 → $19 | $18.01 | +5.50% | 4 | Mar 6, 2026 | |
| TEM Tempus AI | Maintains: Overweight | $85 → $70 | $46.18 | +51.58% | 7 | Mar 3, 2026 | |
| NTRA Natera | Maintains: Overweight | $265 → $250 | $203.19 | +23.04% | 16 | Mar 3, 2026 | |
| GRAL GRAIL | Maintains: Equal-Weight | $110 → $60 | $67.19 | -10.70% | 4 | Feb 24, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Overweight | $656 → $670 | $448.28 | +49.46% | 16 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $250 → $265 | $167.90 | +57.83% | 12 | Dec 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $100 → $105 | $144.41 | -27.29% | 9 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $15 → $12 | $8.12 | +47.78% | 20 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $10 → $8 | $9.23 | -13.33% | 14 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $7 | $14.00 | -50.00% | 2 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $5 | $4.40 | +13.64% | 13 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $32 → $21 | $3.81 | +451.18% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $4 → $2 | $1.22 | +63.93% | 13 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $80 → $40 | $8.41 | +375.62% | 2 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $6 | $2.54 | +136.22% | 3 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $10 | $4.95 | +102.02% | 8 | May 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.75 | $2.06 | +33.50% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $11 → $10 | $1.79 | +458.66% | 10 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $80 → $73 | $118.95 | -38.63% | 9 | Feb 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $350 → $250 | $160.30 | +55.96% | 1 | Aug 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $140 → $100 | $14.93 | +569.79% | 5 | May 12, 2022 |
Personalis
May 12, 2026
Maintains: Equal-Weight
Price Target: $10 → $9
Current: $8.47
Upside: +6.26%
Cytek Biosciences
May 12, 2026
Maintains: Equal-Weight
Price Target: $6 → $5.5
Current: $4.01
Upside: +37.16%
Adaptive Biotechnologies
May 12, 2026
Maintains: Equal-Weight
Price Target: $21 → $18
Current: $13.88
Upside: +29.68%
10x Genomics
May 12, 2026
Maintains: Equal-Weight
Price Target: $20 → $22
Current: $23.68
Upside: -7.09%
Veracyte
Mar 6, 2026
Maintains: Underweight
Price Target: $48 → $37
Current: $45.03
Upside: -17.83%
Stevanato Group
Mar 6, 2026
Maintains: Equal-Weight
Price Target: $24 → $19
Current: $18.01
Upside: +5.50%
Tempus AI
Mar 3, 2026
Maintains: Overweight
Price Target: $85 → $70
Current: $46.18
Upside: +51.58%
Natera
Mar 3, 2026
Maintains: Overweight
Price Target: $265 → $250
Current: $203.19
Upside: +23.04%
GRAIL
Feb 24, 2026
Maintains: Equal-Weight
Price Target: $110 → $60
Current: $67.19
Upside: -10.70%
Thermo Fisher Scientific
Dec 2, 2025
Maintains: Overweight
Price Target: $656 → $670
Current: $448.28
Upside: +49.46%
Dec 2, 2025
Maintains: Overweight
Price Target: $250 → $265
Current: $167.90
Upside: +57.83%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $100 → $105
Current: $144.41
Upside: -27.29%
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $15 → $12
Current: $8.12
Upside: +47.78%
Jul 30, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $9.23
Upside: -13.33%
May 5, 2025
Maintains: Equal-Weight
Price Target: $8 → $7
Current: $14.00
Upside: -50.00%
Mar 25, 2025
Maintains: Equal-Weight
Price Target: $7 → $5
Current: $4.40
Upside: +13.64%
Nov 18, 2024
Maintains: Equal-Weight
Price Target: $32 → $21
Current: $3.81
Upside: +451.18%
Aug 12, 2024
Maintains: Equal-Weight
Price Target: $4 → $2
Current: $1.22
Upside: +63.93%
May 15, 2024
Maintains: Equal-Weight
Price Target: $80 → $40
Current: $8.41
Upside: +375.62%
Aug 3, 2023
Reiterates: Equal-Weight
Price Target: $6
Current: $2.54
Upside: +136.22%
May 10, 2023
Maintains: Overweight
Price Target: $11 → $10
Current: $4.95
Upside: +102.02%
Mar 7, 2023
Reiterates: Equal-Weight
Price Target: $2.75
Current: $2.06
Upside: +33.50%
Feb 21, 2023
Maintains: Equal-Weight
Price Target: $11 → $10
Current: $1.79
Upside: +458.66%
Feb 21, 2023
Maintains: Overweight
Price Target: $80 → $73
Current: $118.95
Upside: -38.63%
Aug 4, 2022
Downgrades: Equal-Weight
Price Target: $350 → $250
Current: $160.30
Upside: +55.96%
May 12, 2022
Maintains: Equal-Weight
Price Target: $140 → $100
Current: $14.93
Upside: +569.79%